These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 6386002)

  • 41. Thrombotic thrombocytopenic purpura. Survival following treatment with aspirin, dipyridamole, and prednisone.
    Rossi EC; Redondo D; Borges WH
    JAMA; 1974 May; 228(9):1141-3. PubMed ID: 4406437
    [No Abstract]   [Full Text] [Related]  

  • 42. ["A.I.C.L.A." controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Part I: Protocol (author's transl)].
    Bousser MG; Eschwege E; Haguenau M; Lefauconnier JM; Touboul D; Touboul PJ
    Rev Neurol (Paris); 1981; 137(5):333-41. PubMed ID: 7027408
    [No Abstract]   [Full Text] [Related]  

  • 43. Acetylsalicylic acid and dipyridamole improve the early patency of aorta-coronary bypass grafts. A double-blind, placebo-controlled, randomized trial.
    Rajah SM; Salter MC; Donaldson DR; Subba Rao R; Boyle RM; Partridge JB; Watson DA
    J Thorac Cardiovasc Surg; 1985 Sep; 90(3):373-7. PubMed ID: 3897722
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety of fixed-dose aspirin-extended-release dipyridamole in patients with ischemic heart disease.
    Crown N; Mysak T
    Am J Health Syst Pharm; 2010 May; 67(9):728-33. PubMed ID: 20410547
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of prostaglandin-mediated platelet-suppressant drugs on acute cardiovascular catastrophes.
    Sherry S
    Adv Prostaglandin Thromboxane Leukot Res; 1982; 10():173-210. PubMed ID: 6216782
    [No Abstract]   [Full Text] [Related]  

  • 46. Prevention of fetal growth retardation with low-dose aspirin: findings of the EPREDA trial.
    Uzan S; Beaufils M; Breart G; Bazin B; Capitant C; Paris J
    Lancet; 1991 Jun; 337(8755):1427-31. PubMed ID: 1675315
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of treatment with aspirin or aspirin/dipyridamole combination in heartworm-negative, heartworm-infected, and embolized heartworm-infected dogs.
    Boudreaux MK; Dillon AR; Ravis WR; Sartin EA; Spano JS
    Am J Vet Res; 1991 Dec; 52(12):1992-9. PubMed ID: 1789513
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [PRoFESS study presented. Change in secondary prevention].
    MMW Fortschr Med; 2003 May; 145 Suppl 2():96-7. PubMed ID: 14579494
    [No Abstract]   [Full Text] [Related]  

  • 49. Randomised placebo controlled trial of aspirin and dipyridamole in the prevention of coronary vein graft occlusion.
    Brooks N; Wright J; Sturridge M; Pepper J; Magee P; Walesby R; Layton C; Honey M; Balcon R
    Br Heart J; 1985 Feb; 53(2):201-7. PubMed ID: 3881108
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Are agents affecting platelet functions clinically useful?
    Verstraete M
    Am J Med; 1976 Dec; 61(6):897-914. PubMed ID: 795299
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Veterans Administration Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: II. Effects of aspirin and dipyridamole on atherosclerotic vascular disease rates.
    Colwell JA; Bingham SF; Abraira C; Anderson JW; Comstock JP; Kwaan HC; Nuttall F
    Diabetes Care; 1986; 9(2):140-8. PubMed ID: 3516608
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ASA-dipyridamole prophylaxis in elective total hip replacement.
    Silvergleid AJ; Bernstein R; Burton DS; Tanner JB; Silverman JF; Schrier SL
    Orthopedics; 1978; 1(1):19-25. PubMed ID: 364364
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A critical appraisal of the clinical efficiency of anti-platelet drugs.
    Lecompte T; Samama M
    Agents Actions Suppl; 1986; 20():203-14. PubMed ID: 3544741
    [No Abstract]   [Full Text] [Related]  

  • 54. Renal scintigraphy and survival of indium-111-labelled platelets in patients with diabetic nephropathy.
    Hooper AH; Tindall H; Barker MJ; Spencer AA; Stainton C; Davies JA
    Nucl Med Commun; 1986 May; 7(5):349-54. PubMed ID: 3737031
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dipyridamole with aspirin for secondary stroke prevention.
    Norrving B
    Lancet; 2006 May; 367(9523):1638-9. PubMed ID: 16714170
    [No Abstract]   [Full Text] [Related]  

  • 56. Platelet-inhibitor therapy in cardiovascular disease. Effective defense against thromboembolism.
    Chesebro JH; Steele PM; Fuster V
    Postgrad Med; 1985 Jul; 78(1):48-50, 57-71. PubMed ID: 3160013
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Platelet inhibitors in the treatment of thrombosis.
    Hirsh J
    Clin Invest Med; 1978; 1(3-4):191-206. PubMed ID: 391458
    [No Abstract]   [Full Text] [Related]  

  • 58. Summary of ongoing clinical trials of platelet-active drugs in cardiovascular disease.
    Passamani ER
    Circulation; 1980 Dec; 62(6 Pt 2):V106-10. PubMed ID: 7002348
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.
    ; Halkes PH; van Gijn J; Kappelle LJ; Koudstaal PJ; Algra A
    Lancet; 2006 May; 367(9523):1665-73. PubMed ID: 16714187
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Distribution of dipyridamole in blood components among post-stroke patients treated with extended release formulation.
    Serebruany V; Sabaeva E; Booze C; Atar OD; Eisert C; Hanley D;
    Thromb Haemost; 2009 Sep; 102(3):538-43. PubMed ID: 19718475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.